© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to August
oral covalent BTK inhibitor
>80% BTK occupancy <5 mg (Ph. I dose esc.)
from fragment-based screen of 11k cmpds
Journal of Medicinal Chemistry
Takeda, San Diego, CA, USA
The Takeda covalent BTK inhibitor clinical candidate, TAK-020, is a highly selective oral covalent BTK inhibitor with safety and tolerability profiles that are promising for both hematologic malignancies and autoimmune…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.